Skip to main content

Trastucip and Tuzucip

Device/Product name
Trastucip and Tuzucip
Active Ingredient
Date of decision
Submission type
New biosimilar medicine
ATC codes
What steps were involved in the decision process

Registration timeline

The following table summarises the key steps and dates for this application.

Description Date
Submission dossier accepted and first round evaluation commenced 2 July 2021
First round evaluation completed 25 February 2022
Sponsor provides responses on questions raised in first round evaluation 9 March 2022
Second round evaluation completed 4 May 2022
Delegate's overall benefit-risk assessment 3 May 2022
Sponsor's pre-Advisory Committee response Not applicable
Advisory Committee meeting Not applicable
Registration decision (Outcome) 7 July 2022
Completion of administrative activities and registration on ARTG 18 July 2022
Number of working days from submission dossier acceptance to registration decision* 216

*Statutory timeframe for standard applications is 255 working days

Date of entry onto ARTG
Original publication date
Black triangle scheme
Dose forms
Powder for injection for intravenous infusion
150 mg
Other ingredients

Histidine hydrochloride monohydrate, histidine, trehalose dihydrate, and polysorbate 20

Pack sizes
Routes of administration
Intravenous infusion

HER2 testing is mandatory prior to initiation of Tuzucip therapy. Dosage of Trastucip and Tuzucip is based on multiple factors including the condition being treated and the body weight of the patient.

For further information refer to the Product Information.

Pregnancy category

Drugs which have caused, are suspected to have caused or may be expected to cause, an increased incidence of human fetal malformations or irreversible damage. These drugs may also have adverse pharmacological effects. Accompanying texts should be consulted for further details.

The use of any medicine during pregnancy requires careful consideration of both risks and benefits by the treating health professional. This must not be used as the sole basis of decision making in the use of medicines during pregnancy. The TGA does not provide advice on the use of medicines in pregnancy for specific cases. More information is available from obstetric drug information services in your State or Territory.
What was approved

Trastucip and Tuzucip (trastuzumab) was approved for the following therapeutic uses:

Early breast cancer

Trastucip and Tuzucip are indicated for the treatment of HER2-positive early breast cancer following surgery, and in association with chemotherapy and, if applicable, radiotherapy.

Locally advanced breast cancer

Trastucip and Tuzucip are indicated for the treatment of HER2-positive locally advanced breast cancer in combination with neoadjuvant chemotherapy followed by adjuvant Trastucip and Tuzucip.

Metastatic breast cancer

Trastucip and Tuzucip are indicated for the treatment of patients with metastatic breast cancer who have tumours that overexpress HER2:

  1. as monotherapy for the treatment of those patients who have received one or more chemotherapy regimens for their metastatic disease;
  2. in combination with taxanes for the treatment of those patients who have not received chemotherapy for their metastatic disease; or
  3. in combination with an aromatase inhibitor for the treatment of post-menopausal patients with hormone-receptor positive metastatic breast cancer

Advanced gastric cancer

Trastucip and Tuzucip are indicated in combination with cisplatin and either capecitabine or 5-FU for the treatment of patients with HER2 positive advanced adenocarcinoma of the stomach or gastro-oesophageal junction who have not received prior anti-cancer treatment for their metastatic disease.

What is this medicine and how does it work
Tuzucip and Trastucip are biosimilar medicine to Herceptin. The human epidermal growth factor receptor 2 (HER2 or c erbB2) proto oncogene encodes for a single transmembrane spanning, receptor like protein of 185 kilodalton (kDa), which is structurally related to the epidermal growth factor receptor.

Trastuzumab has been shown, both in in-vitro assays and in animals, to inhibit the proliferation of human tumour cells that overexpress HER2. In vitro, trastuzumab-mediated antibody dependent cell mediated cytotoxicity (ADCC) has been shown to be preferentially exerted on HER2 overexpressing cancer cells compared with cancer cells that do not overexpress HER2. In animal models in vivo, murine anti-HER2 antibody inhibited the growth of human tumours overexpressing HER2, indicating that the humanised antibody (trastuzumab) is likely also to have anti-proliferative activity in vivo against human breast tumours expressing high levels of HER2.
What post-market commitments will the sponsor undertake
  • For all injectable products the Product Information must be included with the product as a package insert.

Help us improve the Therapeutic Goods Administration site